Monthly Archives: October 2015

//October

CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer

2017-05-16T21:29:57+00:00

Redwood City, Calif. – October 22, 2015 – C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced that it received the CE (Conformité Européenne) mark for its Coldplay CryoBalloon® Focal Ablation System. The product is now available for commercial use initially in parts of Western Europe. Cryoablation is a process that uses extreme cold to precisely destroy or damage diseased tissue while minimizing damage to surrounding healthy tissue.

Click here to see full release.

CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer 2017-05-16T21:29:57+00:00